<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940128-1-00119</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4702 -->  <!-- PJG ITAG l=21 g=1 f=1 --> The agency believes that the proposed processing  <!-- PJG 0012 frnewline --> requirements for cold-process smoked and smoke-flavored products,  <!-- PJG 0012 frnewline --> air-packed and vacuum- or modified atmosphere-packaged, will  <!-- PJG 0012 frnewline --> produce a safe and commercially acceptable product. However,  <!-- PJG 0012 frnewline --> because less data and information are available for these  <!-- PJG 0012 frnewline --> products than for hot-process products, the agency is requesting  <!-- PJG 0012 frnewline --> specific comments, data, and information about these processing  <!-- PJG 0012 frnewline --> parameters and any alternative processing parameters that should  <!-- PJG 0012 frnewline --> be included in the guideline.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 3.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=3 --> Cooling and storage of finished products. <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 -->  Rapid cooling  <!-- PJG 0012 frnewline --> and storage at temperatures of 40  <!-- PJG 0040 degreeslatlong --> &cir;F (4.4  <!-- PJG 0040 degreeslatlong --> &cir;C) or below are  <!-- PJG 0012 frnewline --> essential for all smoked, smoke-flavored, and salted fish  <!-- PJG 0012 frnewline --> products to minimize microbial growth. The exceptions are  <!-- PJG 0012 frnewline --> cold-process air-packaged products that contain a water-phase  <!-- PJG 0012 frnewline --> salt content of 2.5 percent, which should be frozen immediately  <!-- PJG 0012 frnewline --> after processing and remain frozen throughout distribution  <!-- PJG 0012 frnewline --> because of the lower water-phase salt content and lower  <!-- PJG 0012 frnewline --> processing temperatures that may provide an opportunity for food  <!-- PJG 0012 frnewline --> spoilage microorganisms to flourish during storage (see section  <!-- PJG 0012 frnewline --> 5.a.3. of Example 6 of this appendix) and the discussion above). <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Outgrowth of  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=3 --> C. botulinum <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 -->  spores, types A and proteolytic B,  <!-- PJG 0012 frnewline --> and toxin production are inhibited at temperatures of 50  <!-- PJG 0040 degreeslatlong --> &cir;F (10  <!-- PJG 0012 frnewline -->  <!-- PJG 0040 degreeslatlong --> &cir;C) and lower. Spore types E and nonproteolytic B are completely  <!-- PJG 0012 frnewline --> inhibited at temperatures of 38  <!-- PJG 0040 degreeslatlong --> &cir;F (3.3  <!-- PJG 0040 degreeslatlong --> &cir;C) and lower (Refs. 174  <!-- PJG 0012 frnewline --> and 185 through 188).  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> At section 6 of Example 6 of the appendix, the agency is  <!-- PJG 0012 frnewline --> recommending specific time/temperature controls for processing  <!-- PJG 0012 frnewline --> after smoking. These proposed controls are the same as those  <!-- PJG 0012 frnewline --> proposed for after cooking in the cooked, ready-to-eat section of  <!-- PJG 0012 frnewline --> this document (Appendix A, section 6). A full discussion of the  <!-- PJG 0012 frnewline --> controls is provided in section VII.J.3. of this document.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 4.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=3 --> Alternative processing parameters. <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 -->  As this preamble  <!-- PJG 0012 frnewline --> indicates, FDA has tentatively concluded that the TTS processing  <!-- PJG 0012 frnewline --> parameters reflected in this appendix are the minimum necessary  <!-- PJG 0012 frnewline --> to ensure that these products are free from botulinum toxin over  <!-- PJG 0012 frnewline --> their shelf life. FDA has also tentatively concluded that the  <!-- PJG 0012 frnewline --> T-T-S parameters, coupled with good sanitation practices, will  <!-- PJG 0012 frnewline --> also render these products listeria free. Nonetheless, the  <!-- PJG 0012 frnewline --> agency does not wish to discourage the development and use of  <!-- PJG 0012 frnewline --> alternative procedures that are capable of achieving the same  <!-- PJG 0012 frnewline --> outcome.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Consequently, section 11 of Example 6 of this appendix calls  <!-- PJG 0012 frnewline --> for the use of alternative processing parameters when the user  <!-- PJG 0012 frnewline --> can demonstrate the following: (1) For botulism, zero toxin  <!-- PJG 0012 frnewline --> production slightly beyond the expected shelf life of the  <!-- PJG 0012 frnewline --> product, demonstrated through inoculated pack studies under  <!-- PJG 0012 frnewline --> normal and moderate abuse conditions and (2) for listeria, no  <!-- PJG 0012 frnewline --> detectable  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=3 --> L. monocytogenes <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 -->  in the final product. The data  <!-- PJG 0012 frnewline --> demonstrating these outcomes would have to be available to FDA to  <!-- PJG 0012 frnewline --> enable the agency to determine whether they have been achieved.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Example 6 of this appendix states that those data should be  <!-- PJG 0012 frnewline --> part of a processor's HACCP records. FDA asks for comment on  <!-- PJG 0012 frnewline --> whether a third-party scientific expert, or processing authority,  <!-- PJG 0012 frnewline --> should be involved in the development of the data that  <!-- PJG 0012 frnewline --> demonstrate the effectiveness of the alternative procedure.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            